Abstract
Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.
| Original language | English |
|---|---|
| Journal | Current Drug Targets |
| Volume | 17 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - May 29 2016 |
Fingerprint
Keywords
- Anti-tnf
- Crohn’s disease
- Treat to target
- Treatment algorithm
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Clinical Biochemistry
Cite this
Evolving treatment algorithms in crohn’s disease. / Wisniewski, Andrew; Danese, Silvio; peyrin-Biroulet, Laurent.
In: Current Drug Targets, Vol. 17, No. 13, 29.05.2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Evolving treatment algorithms in crohn’s disease
AU - Wisniewski, Andrew
AU - Danese, Silvio
AU - peyrin-Biroulet, Laurent
PY - 2016/5/29
Y1 - 2016/5/29
N2 - Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.
AB - Crohn’s disease (CD) is a chronic, disabling and destructive condition. Half of the patients will develop some bowel damage (stricture, fistula and/or abscess). Current therapeutic strategies failed to alter its natural history. Treatment of CD has evolved over a quarter of a century from a linear sequence of treatment intensification to a complex algorithm focused on individualized patient care by looking beyond symptoms. A tight monitoring of objective signs of inflammation and a treat to target approach are probably the only way to change patients’ life and disease course. We now seek to optimize our therapeutic tools according to patient profile, disease phenotype and the unique pharmacodynamics that ensues. This article explores the evolving concepts in assessing disease severity, selecting rigorous treatment end-targets, initiating an effective therapeutic therapy, and managing secondary loss of response.
KW - Anti-tnf
KW - Crohn’s disease
KW - Treat to target
KW - Treatment algorithm
UR - http://www.scopus.com/inward/record.url?scp=85010670061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010670061&partnerID=8YFLogxK
U2 - 10.2174/1389450117666160607075557
DO - 10.2174/1389450117666160607075557
M3 - Review article
AN - SCOPUS:85010670061
VL - 17
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 13
ER -